WO2007115385A3 - Transfer plasmidic vector and recombinant canarypox virus - Google Patents

Transfer plasmidic vector and recombinant canarypox virus Download PDF

Info

Publication number
WO2007115385A3
WO2007115385A3 PCT/BR2007/000087 BR2007000087W WO2007115385A3 WO 2007115385 A3 WO2007115385 A3 WO 2007115385A3 BR 2007000087 W BR2007000087 W BR 2007000087W WO 2007115385 A3 WO2007115385 A3 WO 2007115385A3
Authority
WO
WIPO (PCT)
Prior art keywords
canarypox virus
virus
seq
transfer
plasmidic
Prior art date
Application number
PCT/BR2007/000087
Other languages
French (fr)
Other versions
WO2007115385A2 (en
Inventor
Gabriela Calamante
Grand Maria Daniela Conte
Elisa Cristina Carrillo
Original Assignee
Inst Nac De Tecnologia Agropec
Biogenesis Bago Saude Animal L
Gabriela Calamante
Grand Maria Daniela Conte
Elisa Cristina Carrillo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nac De Tecnologia Agropec, Biogenesis Bago Saude Animal L, Gabriela Calamante, Grand Maria Daniela Conte, Elisa Cristina Carrillo filed Critical Inst Nac De Tecnologia Agropec
Publication of WO2007115385A2 publication Critical patent/WO2007115385A2/en
Publication of WO2007115385A3 publication Critical patent/WO2007115385A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A recombinant virus from the canarypox virus (CNPV) is provided, being the virus capable of acting in vivo as an expression vector of foreign genes inserted in genomic regions non-essential for viral replication, that show genetic stability, wherein said genomic regions correspond to at least a gene selected from CNPV018 (SEQ ID No 1), CNPV048 (SEQ ID No 2) and CNPV134 (SEQ ID No 3) of the canarypox virus genome. A plasmidic transfer vector susceptible of homologous recombination with a canarypox virus is provided. Vaccines and immunization methods are also provided.
PCT/BR2007/000087 2006-04-10 2007-04-09 Transfer plasmidic vector and recombinant canarypox virus WO2007115385A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP060101408 2006-04-10
ARP060101408A AR052743A1 (en) 2006-04-11 2006-04-11 PLASMIDIC TRANSFER VECTOR AND RECOMBINANT CANARYPOX VIRUS

Publications (2)

Publication Number Publication Date
WO2007115385A2 WO2007115385A2 (en) 2007-10-18
WO2007115385A3 true WO2007115385A3 (en) 2008-01-10

Family

ID=37908497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2007/000087 WO2007115385A2 (en) 2006-04-10 2007-04-09 Transfer plasmidic vector and recombinant canarypox virus

Country Status (2)

Country Link
AR (1) AR052743A1 (en)
WO (1) WO2007115385A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103740758B (en) * 2013-12-18 2015-03-18 广东华南联合疫苗开发院有限公司 Recombinant baculovirus vector, virus like particle, preparation method and use
CN103710384A (en) * 2013-12-18 2014-04-09 广东华南联合疫苗开发院有限公司 Picornaviridae recombinant vector, virus like particle, and preparation method and use of virus like particle
CN113388587B (en) * 2021-07-06 2023-09-26 天康制药股份有限公司 Recombinant bovine nodavirus expressing bovine viral diarrhea E2 gene and application thereof
CN116656730B (en) * 2023-05-25 2024-03-19 军事科学院军事医学研究院军事兽医研究所 Recombinant canary pox virus expressing rabies virus G, M protein and construction method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008789A1 (en) * 1990-11-20 1992-05-29 Virogenetics Corporation Measles virus recombinant poxvirus vaccine
WO1999003885A1 (en) * 1997-07-18 1999-01-28 Transgene S.A. Antitumoral composition based on immunogenic polypeptide with modified cell location
WO2003095656A1 (en) * 2002-05-14 2003-11-20 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Recombinant fowlpox virus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008789A1 (en) * 1990-11-20 1992-05-29 Virogenetics Corporation Measles virus recombinant poxvirus vaccine
WO1999003885A1 (en) * 1997-07-18 1999-01-28 Transgene S.A. Antitumoral composition based on immunogenic polypeptide with modified cell location
WO2003095656A1 (en) * 2002-05-14 2003-11-20 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Recombinant fowlpox virus

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
COX W I ET AL: "INDUCTION OF CYTOTOXIC T LYMPHOCYTES BY RECOMBINANT CANARYPOX (ALVAC) AND ATTENUATED VACCINIA (NYVAC) VIRUSES EXPRESSING THE HIV-1 ENVELOPE GLYCOPROTEIN", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 195, 1993, pages 845 - 850, XP002085837, ISSN: 0042-6822 *
PAOLETTI ENZO: "Applications of pox virus vectors to vaccination: An update", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 93, no. 21, October 1996 (1996-10-01), pages 11349 - 11353, XP002135943, ISSN: 0027-8424 *
SOMOGYI P ET AL: "FOWLPOX VIRUS HOST RANGE RESTRICTION: GENE EXPRESSION, DNA REPLICATION, AND MORPHOGENESIS IN NONPERMISSIVE MAMMALIAN CELLS", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 197, no. 1, November 1993 (1993-11-01), pages 439 - 444, XP001083667, ISSN: 0042-6822 *
TULMAN E R ET AL: "The genome of canarypox virus.", JOURNAL OF VIROLOGY, vol. 78, no. 1, January 2004 (2004-01-01), pages 353 - 366, XP002454494, ISSN: 0022-538X *

Also Published As

Publication number Publication date
WO2007115385A2 (en) 2007-10-18
AR052743A1 (en) 2007-03-28

Similar Documents

Publication Publication Date Title
MX2010007336A (en) Protein expression systems.
WO2007097820A3 (en) Viral gene products and methods for vaccination to prevent viral associated diseases
IL204539A (en) Poxvirus comprising defective genes and a suicide gene, a pharmaceutical composition comprising it and a process for its preparation
WO2006069064A3 (en) Conserved hbv and hcv sequences useful for gene silencing
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
JP2010259446A5 (en)
MX2007009628A (en) Replication-deficient rna viruses as vaccines.
TW200636070A (en) Rescue of influenza virus
JP2013507935A5 (en)
EP2527445A3 (en) Treatment and prevention of influenza
WO2007115385A3 (en) Transfer plasmidic vector and recombinant canarypox virus
EP1721981A4 (en) Recombinant varicella-zoster virus
JP2011234731A (en) Vector for integration of heterologous sequence into poxviral genome
WO2006013103A3 (en) Inducible gene expression
WO2009036933A3 (en) Down regulation of the gene expression by means of nucleic acid-loaded virus-like particles
MX2021004455A (en) Compositions and methods for delivering transgenes.
JP2004506018A5 (en)
RU2018130683A (en) ATTENUATED INFECTIOUS BRONCHITIS VIRUS
EP2471937A3 (en) Recombinant polyvalent vaccine
WO2008039937A3 (en) Blocking of gene expression in eukaryotic cells
WO2008045601A3 (en) Adenovirus-based genetic vaccines for biodefense
WO2008133137A1 (en) Vector for gene therapy
EP1149917A3 (en) Hepatitis B virus vectors for gene therapy
WO2008108344A1 (en) Cell for gene therapy of lcat deficiency, and replication-deficient retrovirus vector and plasmid for use in the production of the cell
WO2010042743A3 (en) Chimeric multiplexes, compositions, and methods for using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07719255

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07719255

Country of ref document: EP

Kind code of ref document: A2